Quinn Ostrom

Preprint · June 25, 2026 ABSTRACTBackgroundMost genomic studies of adult-type diffuse gliomas have focused on predominantly European ancestry populations, lim ... Full text Cite

Gabapentin repurposing for glioblastoma therapy: Real-world data analyses augmented by use of active comparators.

Preprint · September 27, 2025 Glioblastoma 'hijacks' neuronal pathways to drive tumor growth, and drugs affecting the function of these pathways may potentiate survival gains. Recent studies have suggested clinical benefits with post-diagnostic use of gabapentin. We assessed the impact ... Full text Link to item Cite

Elevated meningioma risk among individuals who are Non-Hispanic Black is strongest for grade 2-3 tumors and synergistically modified by male sex.

Preprint · June 13, 2024 BACKGROUND: Meningioma risk factors include older age, female sex, and African-American race. There are limited data exploring how meningioma risk in African-Americans varies across the lifespan, interacts with sex, and differs by tumor grade. METHODS: The ... Full text Link to item Cite

Atopy improves survival and decreases risk of brain metastasis in cutaneous melanoma.

Preprint · May 15, 2024 IMPORTANCE: Development of new therapies in melanoma has increased survival, and as a result more patients are living to develop brain metastasis (BrM). Identifying patients at increased risk of BrM is therefore of significant public health importance. OBJ ... Full text Link to item Cite

Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.

Preprint · January 11, 2024 BACKGROUND: Polygenic risk scores (PRS) aggregate the contribution of many risk variants to provide a personalized genetic susceptibility profile. Since sample sizes of glioma genome-wide association studies (GWAS) remain modest, there is a need to find ef ... Full text Link to item Cite

Glioblastoma and other intracranial tumors elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses

Preprint · 2023 Intracranial tumors present unique challenges for immunotherapy. These can include both local and systemic modes of immune suppression whose mechanistic underpinnings are incompletely understood. Here, we reveal that tumors harbored intracranially elicit s ... Full text Cite